Important considerations include: GLP-1 agonists are generally well-tolerated in people with hypertension They do not typically cause dangerous drops in blood pressure Dehydration from gastrointestinal side effects (nausea, vomiting, diarrhoea) can occasionally affect blood pressure and kidney function, so maintaining adequate fluid intake is important If you take diuretics (water tablets), ACE inhibitors or ARBs for blood pressure, your doctor may monitor you more closely during the initial weeks of GLP-1 therapy Seek medical advice promptly if you experience persistent gastrointestinal symptoms that prevent adequate fluid intake NICE guidance (NG28) supports the use of GLP-1 agonists in people with type 2 diabetes who meet specific criteria, with preference for agents with proven cardiovascular benefits in those with established cardiovascular disease
Any new or changing lesions should be reported, particularly if they stand out as being different, or are growing, crusting or bleeding
Indeed, hyperinsulinemia-mediated increases in TKT expression are directly correlated to the development of MAFLD
Rachele, are curious whether lower doses of tirzepatide could help as a preventive measure
Okur MN, Fang EF, Fivenson EM, Tiwari V, Croteau DL, Bohr VA (2020) Cockayne syndrome proteins CSA and CSB maintain mitochondrial homeostasis through NAD(+) signaling
